Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

Novavax also announced another, unnamed, large pharma company has also signed a deal to license the adjuvant for use in ...

Gaithersburg: Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M adjuvant, has announced that ...

Novavax, a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, is proud to announce an exciting new partnership with the Los Angeles Rams aimed at "Protecting the Rams House" ...

As we discussed last quarter, the partnership with Sanofi is a license and collaboration agreement that combines Novavax's ...

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...

GAITHERSBURG, Md., Oct. 16, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food ...

U.S. FDA removes clinical hold on Investigational New Drug application for COVID-19-Influenza Combination and stand-alone influenza vaccine candidates Achieved total ...

The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

Novavax, Inc. ( NASDAQ: NVAX) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M adjuvant, today ...